Researchers from The University of Texas Medical Branch at Galveston and Tekmira Pharmaceuticals Corp., have successfully developed a post-exposure treatment that is effective against a specific strain of the Ebola virus that killed thousands of people in West Africa.
Lead UTMB author Thomas Geisbert. Photo courtesy of the University of Texas Medical Branch at Galveston
Researchers from The University of Texas Medical Branch at Galveston and Tekmira Pharmaceuticals Corp., have successfully developed a post-exposure treatment that is effective against a specific strain of the Ebola virus that killed thousands of people in West Africa.
The study results, in the April 22 edition of Nature Journal, demonstrated that the treatment is the first to be shown effective against the new Makona outbreak strain of Ebola in animals that were infected with the virus and exhibited symptoms of the disease.
The treatment uses a sequence specific short strand of RNA, known as siRNA, designed to target and interfere with the Ebola virus, rendering it harmless. One of the advantages of this approach is the ability to quickly modify it to different viral strains.
"We quickly adapted our candidate treatment to target the Makona outbreak strain of Ebola virus," said UTMB's Thomas Geisbert, professor of microbiology and immunology. "We were able to protect all of our nonhuman primates against a lethal Makona Ebola infection when treatment began three days following infection. At this point, those infected showed clinical signs of disease and had detectable levels of virus in their blood."
Although all infected animals showed evidence of advanced disease, those receiving treatment had milder symptoms and recovered fully. The untreated controls succumbed to the disease on days eight and nine, which is similar to that reported in the field after patients begin showing symptoms of Ebola.
This treatment also protected against liver and kidney dysfunction and blood disorders that occur during an Ebola infection. These results indicate that the treatment may confer protective benefits that go beyond improving survival rates and effective control of virus levels in the body.
"This study demonstrates that we can rapidly and accurately adapt our siRNA-LNP technology to target genetic sequences emerging from new Ebola virus outbreaks," said Dr. Mark Murray, president and CEO of Tekmira Pharmaceuticals.
The Tekmira siRNA-based therapeutic is now being evaluated in Ebola-infected patients in Sierra Leone.
Other authors include UTMB's Chad E. Mire, Joan B. Geisbert, Krystle N. Agans, Daniel J. Deer, Karla A. Fenton and Emily P. Thi, Amy C.H. Lee, Joy Z. Zhou, Nicholas M. Snead, Trisha R. Barnard and Ian MacLachlan from Tekmira Pharmaceuticals.
This research was supported by the National Institutes of Health.
University of Texas Medical Branch at Galveston
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Reducing Hidden Risks: Why Sharps Injuries Still Go Unreported
July 18th 2025Despite being a well-known occupational hazard, sharps injuries continue to occur in health care facilities and are often underreported, underestimated, and inadequately addressed. A recent interview with sharps safety advocate Amanda Heitman, BSN, RN, CNOR, a perioperative educational consultant, reveals why change is overdue and what new tools and guidance can help.
New Study Explores Oral Vancomycin to Prevent C difficile Recurrence, But Questions Remain
July 17th 2025A new clinical trial explores the use of low-dose oral vancomycin to prevent Clostridioides difficile recurrence in high-risk patients taking antibiotics. While the data suggest a possible benefit, the findings stop short of statistical significance and raise red flags about vancomycin-resistant Enterococcus (VRE), underscoring the delicate balance between prevention and antimicrobial stewardship.
What Lies Beneath: Why Borescopes Are Essential for Verifying Surgical Instrument Cleanliness
July 16th 2025Despite their smooth, polished exteriors, surgical instruments often harbor dangerous contaminants deep inside their lumens. At the HSPA25 and APIC25 conferences, Cori L. Ofstead, MSPH, and her colleagues revealed why borescopes are an indispensable tool for sterile processing teams, offering the only reliable way to verify internal cleanliness and improve sterile processing effectiveness to prevent patient harm.
The Next Frontier in Infection Control: AI-Driven Operating Rooms
Published: July 15th 2025 | Updated: July 15th 2025Discover how AI-powered sensors, smart surveillance, and advanced analytics are revolutionizing infection prevention in the OR. Herman DeBoard, PhD, discusses how these technologies safeguard sterile fields, reduce SSIs, and help hospitals balance operational efficiency with patient safety.
Targeting Uncertainty: Why Pregnancy May Be the Best Time to Build Vaccine Confidence
July 15th 2025New national survey data reveal high uncertainty among pregnant individuals—especially first-time parents—about vaccinating their future children, underscoring the value of proactive engagement to strengthen infection prevention.